Kronos Common Stock Total Equity from 2010 to 2024
| KRON Stock | USD 0.95 0.01 1.04% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 65.5 K | Current Value 39.2 K | Quarterly Volatility 24.6 K |
Check Kronos Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kronos Bio's main balance sheet or income statement drivers, such as Net Interest Income of 9.5 M, Interest Income of 9.5 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 9.18, Dividend Yield of 0.0 or PTB Ratio of 0.48. Kronos financial statements analysis is a perfect complement when working with Kronos Bio Valuation or Volatility modules.
Kronos | Common Stock Total Equity |
Latest Kronos Bio's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Kronos Bio over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Kronos Bio's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kronos Bio's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Kronos Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 21,514 | |
| Geometric Mean | 11,160 | |
| Coefficient Of Variation | 114.19 | |
| Mean Deviation | 21,885 | |
| Median | 5,000 | |
| Standard Deviation | 24,567 | |
| Sample Variance | 603.5M | |
| Range | 60.5K | |
| R-Value | 0.79 | |
| Mean Square Error | 244.1M | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 4,341 | |
| Total Sum of Squares | 8.4B |
Kronos Common Stock Total Equity History
About Kronos Bio Financial Statements
Kronos Bio investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Kronos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 65.5 K | 39.2 K |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Kronos Stock
| 0.71 | VTRS | Viatris | PairCorr |
| 0.65 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.65 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.65 | GILD | Gilead Sciences | PairCorr |
| 0.44 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Kronos Bio Correlation against competitors. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.